7. License Agreements (Details Narrative) - USD ($)	1 Months Ended						3 Months Ended		9 Months Ended
	Jul. 31, 2022	Apr. 30, 2022	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020	Aug. 31, 2019	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Business Combination, Separately Recognized Transactions [Line Items]
Research and development expense							$ 14,750,000	$ 8,683,000	$ 43,115,000	$ 27,103,000
Stock Issued During Period, Value, New Issues										$ 97,957,000
Other Accrued Liabilities, Current							3,000		3,000		$ 25,000
Assetsfrom Vyera Pharmaceuticals [Member]
Business Combination, Separately Recognized Transactions [Line Items]
Business Combination, Separately Recognized Transactions, Description		On April 8, 2022, Seelos Corporation (“STI”), a wholly-owned subsidiary of the Company, and Vyera, entered into an amendment (the “Amendment”) to the Asset Purchase Agreement by and between STI and Vyera, dated March 6, 2018 (as amended by a first amendment thereto entered into on May 18, 2018, a second amendment thereto entered into on December 31, 2018, a third amendment thereto entered into on October 15, 2019 and a fourth amendment thereto entered into on February 15, 2021, the “Vyera Purchase Agreement”). Pursuant to the Vyera Purchase Agreement, STI acquired the assets and liabilities of Vyera related to a product candidate currently referred to as SLS-002 (intranasal ketamine) (the “Vyera Assets”) and agreed, among other things, to make certain development and commercialization milestone payments and royalty payments related to the Vyera Assets (the “Milestone and Royalty Payment Obligations”) and further agreed that in the event that the Company sold, directly or indirectly, all or substantially all of the Vyera Assets to a third party, then the Company would pay Vyera an amount equal to 4% of the net proceeds actually received by the Company as an upfront payment in such sale (the “Change of Control Payment Obligation”).
[custom:CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement]		$ 4,000,000.0
Stock Issued During Period, Shares, New Issues	500,000	500,000
Research and development expense							5,800,000
Stock Issued During Period, Value, New Issues	$ 800,000
Other Accrued Liabilities, Current							1,000,000.0		1,000,000.0
Weg License Agreement [Member]
Business Combination, Separately Recognized Transactions [Line Items]
Business Combination, Separately Recognized Transactions, Description						On August 29, 2019, the Company entered into an amended and restated exclusive license agreement with Stuart Weg, M.D. (the “Weg License Agreement”), pursuant to which the Company was granted an exclusive worldwide license to certain intellectual property and regulatory materials related to SLS-002. Under the terms of the Weg License Agreement, the Company paid an upfront license fee of $75,000 upon execution of the agreement. The Company agreed to pay additional consideration to Dr. Weg as follows: (i) $0.1 million on January 2, 2020, (ii) $0.125 million on January 2, 2021, and (iii) in the event the FDA has not approved an NDA for a product containing ketamine in any dosage on or before December 31, 2021, $
[custom:NonrefundableCashPayment]			$ 200,000	$ 125,000	$ 100,000
Asset Acquisition, Contingent Consideration, Liability, Current							$ 0		$ 0